These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 7374415)

  • 101. Normalization of low-density lipoproteins in familial hypercholesterolemia.
    Spodick DH
    N Engl J Med; 1981 May; 304(22):1361-2. PubMed ID: 7219490
    [No Abstract]   [Full Text] [Related]  

  • 102. [Modification of pathologic fatty acid patterns in old age by combined clofibrinic and nicotinic acid treatment].
    Reuter W
    Z Alternsforsch; 1983; 38(5):383-8. PubMed ID: 6659567
    [TBL] [Abstract][Full Text] [Related]  

  • 103. [Effect of bezafibrate on disorders of lipid metabolism].
    Stryjek-Kamińska D; Ilińska-Debniak K; Bartosiewicz W; Szczepanik Z
    Pol Tyg Lek; 1983 Dec; 38(50):1567-71. PubMed ID: 6379618
    [No Abstract]   [Full Text] [Related]  

  • 104. Dietary and drug treatment of hyperlipoproteinemia.
    Mordasini R; Oster P; Riesen W
    Ric Clin Lab; 1982; 12(1):117-25. PubMed ID: 7046017
    [No Abstract]   [Full Text] [Related]  

  • 105. Effect of a new niacin derivative (nicotinic hexaester of D-glucitol) on type IIA, IIB and IV hyperlipoproteinemia in man.
    Avogaro P; Bittolo-Bon G; Pais M; Taroni GC
    Pharmacol Res Commun; 1977 Jun; 9(6):599-606. PubMed ID: 197548
    [No Abstract]   [Full Text] [Related]  

  • 106. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. I. Changes in lipid levels after treatment (the "net" reduction)].
    Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Jamska B; Nowacki G
    Przegl Lek; 1987; 44(12):828-36. PubMed ID: 3330252
    [No Abstract]   [Full Text] [Related]  

  • 107. [Evaluation of a sulfomucopolysaccharide (3GS) in the treatment of hyperlipoproteinemias].
    Palmieri G; Perego M; Nazzari M; Casalini F
    Clin Ter; 1982 Jun; 101(6):603-14. PubMed ID: 7128029
    [No Abstract]   [Full Text] [Related]  

  • 108. [Anti-atherosclerotic properties of eicosapentaenoic acid: clinico-experimental study].
    Reng LC; Vasil'ev AV; Orekhov AN; Tutel'ian VA
    Vopr Pitan; 1989; (3):20-2. PubMed ID: 2552676
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Hypolipidemic effects of bezafibrate: studies in Italy.
    Postiglione A; Riccardi G; Saldalamacchia G
    Monogr Atheroscler; 1986; 14():198-202. PubMed ID: 3526125
    [No Abstract]   [Full Text] [Related]  

  • 110. [Hyperlipoproteinemias: significance--diagnosis--therapy].
    Schwandt P
    Internist (Berl); 1971 Nov; 12(11):481-7. PubMed ID: 4943880
    [No Abstract]   [Full Text] [Related]  

  • 111. [Surgical correction of hyperlipoproteinemia in patients with normal and excessive body weight].
    Lebedev LV; Sedletskiĭ IuI
    Vestn Khir Im I I Grek; 1982 Dec; 129(12):56-60. PubMed ID: 7168115
    [No Abstract]   [Full Text] [Related]  

  • 112. Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and in patients with diabetes mellitus and mixed hyperlipoproteinemia.
    Geiss HC; Schwandt P; Parhofer KG
    Exp Clin Endocrinol Diabetes; 2002 Jun; 110(4):182-7. PubMed ID: 12058342
    [TBL] [Abstract][Full Text] [Related]  

  • 113. [Therapeutic effect of etofyllinclofibrate in disordered lipid and uric acid metabolism].
    Fiegel G
    Med Welt; 1982 Mar; 33(9):334-6. PubMed ID: 7045566
    [No Abstract]   [Full Text] [Related]  

  • 114. [Tolerability and side-effects of bis-(hydroxy-2-ethylthio)-1,10-decane (BS 530) as compared with clofibrate in the therapy of hyperlipemia].
    Colombo L; Monarca A; Goldberg D; Zanetta R
    Clin Ter; 1979 Oct; 91(2):155-71. PubMed ID: 540479
    [No Abstract]   [Full Text] [Related]  

  • 115. Hypercholesterolemia in childhood.
    West RJ; Lloyd JK
    Adv Pediatr; 1979; 26():1-34. PubMed ID: 396772
    [No Abstract]   [Full Text] [Related]  

  • 116. [Effect of clofibric acid on fatty acid metabolism in HLP patients in the 2d half of life].
    Reuter W
    Z Alternsforsch; 1982; 37(6):409-16. PubMed ID: 7164480
    [TBL] [Abstract][Full Text] [Related]  

  • 117. [Lipid depression by etofibrate in a comparative study in rats with artificial hyperlipidemia].
    Sterner W; Schultz A
    Arzneimittelforschung; 1974 Dec; 24(12):1990-2. PubMed ID: 4480360
    [No Abstract]   [Full Text] [Related]  

  • 118. Behaviour of uricemia in hyperlipoproteinemic subjects.
    Zdrenghea D; Marta D; Constantinescu M; Cucuianu M
    Med Interne; 1980; 18(4):385-90. PubMed ID: 7455583
    [TBL] [Abstract][Full Text] [Related]  

  • 119. [Effects of polyenylphosphatidylcholine (PPC) on serum lipids in patients with hyperlipoproteinemia. A double-blind study].
    Horsch AK; Majolk I; Heuck CC; Göpfert E
    Vasa; 1986; 15(3):251-5. PubMed ID: 3532609
    [No Abstract]   [Full Text] [Related]  

  • 120. [Blood plasma prostaglandins and their role in disorders of lipid metabolism in ischemic heart disease caused by coronary arteriosclerosis].
    Bochkareva EV; Zykova VP; Lobova NM; Polesskiĭ VA; Gadzhanova SI
    Ter Arkh; 1980; 52(5):18-22. PubMed ID: 7404361
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.